Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis.

• Increased awareness of JAKi-associated weight gain may be significant for patient counselling and decision making • This study has implications for future exploration of the therapeutic potential of JAKi in cachexia and metabolic disease Conflicts of interest Dr Abu-Hilal has been speaker, advisor and/or received honoraria from AbbVie, Biojamp, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, Galderma, Hikma Pharmaceuticals, Incyte, Janssen, Leo, L’Oreal, La Roche Posay, Medexus, Novartis, Pfizer, Recordati, Sanofi Regeneron, and Sun Pharma.

also in 13,097 other papers